consolid intraperiton cisplatin first-lin therapi advanc ovarian cancer seventy-f patient advanc epitheli ovarian cancer combin modal regimen system induct chemotherapi intraperiton therapi ipt patient underw initi surgeri and/or cytoreduct cisplatin IV day cyclophosphamid day week cycl patient ipt elig intraperiton IP cathet ipt cisplatin day IV day week cycl patient clinic complet respons ccr second-look laparotomi sll patient induct phase elig ipt patient therapi phase toxic combin modal approach accept previou experi drug thirty-two patient ipt ccr sll patient twenti recurr ccr patient patient sll median surviv patient month median surviv amount residu diseas initi surgeri month bulki month minim residu perform statu PS month PS month PS patient bulki tumor like consolid ipt phase incorpor IP cisplatin first-lin regimen treatment ovarian cancer major impact surviv treat patient histor control seri IV ipt cisplatin cyclophosphamid feasibl accept toxic impact respons surviv good-prognosi patient 